학술논문
The comorbidity and co-medication profile of patients with progressive supranuclear palsy.
Document Type
Article
Author
Greten, Stephan; Wegner, Florian; Jensen, Ida; Krey, Lea; Rogozinski, Sophia; Fehring, Meret; Heine, Johanne; Doll-Lee, Johanna; Pötter-Nerger, Monika; Zeitzschel, Molly; Hagena, Keno; Pedrosa, David J.; Eggers, Carsten; Bürk, Katrin; Trenkwalder, Claudia; Claus, Inga; Warnecke, Tobias; Süß, Patrick; Winkler, Jürgen; Gruber, Doreen
Source
Subject
*PROGRESSIVE supranuclear palsy
*NEUROLOGICAL disorders
*DRUG interactions
*CEREBROVASCULAR disease
*COMORBIDITY
*
*
*
*
Language
ISSN
0340-5354
Abstract
Background: Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients. Objectives: To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease. Methods: Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®. Results: In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions. Conclusions: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients. [ABSTRACT FROM AUTHOR]